Company Encyclopedia
View More
name
Recursion Pharmaceuticals
RXRX.US
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.
1.907 T
RXRX.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking201/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-91.06%E
    • Profit Margin-1637.81%E
    • Gross Margin-2523.17%E
  • Growth ScoreD
    • Revenue YoY-32.98%E
    • Net Profit YoY-89.42%E
    • Total Assets YoY92.64%A
    • Net Assets YoY99.59%A
  • Cash ScoreD
    • Cash Flow Margin-6.11%D
    • OCF YoY-32.98%E
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreB
    • Gearing Ratio25.19%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock market midday update: Recursion Pharmaceuticals up 9.35%, executives increase holdings and new cooperation agreement boosts confidence

    Recursion Pharmaceuticals rose 9.35%; Precision Science rose 0.32%, with a transaction volume of USD 1.391 billion; AbbVie rose 3.52%, with a transaction volume of USD 1.117 billion; Gilead Sciences rose 2.25%, with a transaction volume of USD 771 million; Amgen rose 2.39%, with a market value of USD 184 billion

    Tracking Unusual Activity·
    US
    RXRX
    +8.31%
    Tracking Unusual Activity·
    US
    RXRX
    +8.31%

    CEO Gibson Sells 40,000 ($166.4K) Of Recursion Pharmaceuticals Inc [RXRX]

    CEO Gibson Christopher of Recursion Pharmaceuticals Inc [RXRX] sold 40,000 shares worth $166,400 on November 19, 2025, as disclosed in a Form 4 filing with the SEC. The sale was executed under a prearranged trading plan (10b5-1).

    Reuters·
    US
    RXRX
    +8.31%
    Reuters·
    US
    RXRX
    +8.31%

    Officer/Dir Khan Surrenders 17,584 Of Recursion Pharmaceuticals Inc [RXRX]

    Khan Najat, Officer and Director of Recursion Pharmaceuticals Inc [RXRX], surrendered 17,584 shares at $4.14 each, valued at $72,798, to cover option exercise costs and/or tax liabilities. The transaction was disclosed in a Form 4 filed with the SEC on November 19, 2025. Najat's ending holdings are 735,538 shares directly.

    Reuters·
    US
    RXRX
    +8.31%
    Reuters·
    US
    RXRX
    +8.31%

    CFO Taylor Surrenders 11,908 Of Recursion Pharmaceuticals Inc [RXRX]

    CFO Taylor Ben R of Recursion Pharmaceuticals Inc [RXRX] surrendered 11,908 shares at $4.14 each, valued at $49,299, to cover option exercise costs and/or tax liabilities. His ending holdings are 792,261 shares. This was disclosed in a Form 4 filed with the SEC on November 19, 2025.

    Reuters·
    US
    RXRX
    +8.31%
    Reuters·
    US
    RXRX
    +8.31%

    Recursion Pharmaceuticals (RXRX): Assessing Valuation Following CEO Appointment and Disappointing Earnings Results

    Recursion Pharmaceuticals (RXRX) has appointed Najat Khan as CEO starting January 2026, amidst disappointing quarterly earnings showing lower revenue and increased losses. The stock has dropped 35.5% year-to-date, raising concerns about growth prospects. Analysts estimate the fair value at $6.30, while a DCF model suggests a lower value of $4.41, indicating potential overvaluation. Investors are urged to consider the risks and opportunities in the biotech sector, as the company integrates advanced AI tools for drug development.

    Simplywall·
    US
    RXRX
    +8.31%
    Simplywall·
    US
    RXRX
    +8.31%
    Posts
    View More

    It's a liquidity crisis in essence! Waiting for the Fed and Trump the big boss! This is the only way out. Still gotta eat well!$Tesla(TSLA.US)$Rocket Lab(RKLB.US)$Recursion Pharmaceuticals(RXRX.US)$XT...

    • 0

    Today, the Qwen app was released, and finally, Alibaba is seriously addressing the 2C market. I immediately conducted a test. I called the most token-consuming DeepReseach to run RXRX, which I current...

    $Tesla(TSLA.US) $Rocket Lab(RKLB.US) $Recursion Pharmaceuticals(RXRX.US) Such a sharp decline, saying it doesn't hurt is definitely a lie. It hurts, it really hurts, it's excruciating. But these past ...

    • 0

    $Recursion Pharmaceuticals(RXRX.US) Small pre-market nibble. Act within your means. The market is volatile, take care.

    • 0